ANI Pharma (ANIP) Q3 2026 Earnings Call Transcript

ANI Pharmaceuticals reported Q3 2026 revenue of $290.8 million, up 28% year over year, adjusted EBITDA of $82.3 million, up 40%, and adjusted diluted EPS of $2.70 versus $2.04 a year earlier. It narrowed 2026 revenue guidance to $1.085 billion–$1.125 billion and lowered Cortrophin Gel guidance to $480 million–$500 million amid specialty-pharmacy capacity constraints, while raising adjusted EBITDA guidance to $290 million–$300 million and EPS guidance to $9.37–$9.71. ANI also made a $560 million all-cash offer for Egetis Therapeutics; management expects the deal to be dilutive to adjusted EPS in year one and pro forma net leverage of about 2.7x after closing. The company cited record Q3 operating cash flow of $83.8 million and year-to-date share repurchases of $20 million.

Analysis

The key read-through for ANIP is a split between demand creation and revenue realization. Cortrophin’s funnel is expanding, but that is not yet equivalent to paid starts: specialty-pharmacy throughput and prescriber onboarding are constraining conversion, with potential spillover into established indications. The raised earnings outlook appears better supported by generics, mix and cost discipline than by a near-term Cortrophin rebound. Watch fulfilled starts and time-to-first-fill—not prescriber counts—as the decisive 1–3 month indicators. If those improve, delayed demand could support 2027 growth; if not, the current funnel may overstate monetizable demand.

The Egetis offer adds a separate, longer-dated execution bet. The diagnosed and treated populations are only a starting base, not proof of rapid penetration. Annualized WAC applied to EAP patients is not commercial revenue: confirm dose/weight mix, payer coverage, net price, transition timing and whether access-program patients convert. Broadening diagnosis may take years, while launch spending and acquisition debt arrive earlier. This could dilute near-term EPS and limit buyback capacity even if the asset ultimately scales. HRMY’s royalty stream is a modest diversification source, not a material hedge for either launch risk. For Egetis holders, deal completion and terms matter more than ANIP’s operating thesis; no spread trade is supportable without market prices and tender details. Contrarian point: strong reported growth can obscure a real execution bottleneck, but the guidance reset may also have priced in too much permanence before the expanded pharmacy network has had time to work.

Key Decisions for Investors

• ANIP: Do not chase the headline earnings strength. Consider a staged long only after evidence of better Cortrophin conversion—fulfilled starts/time-to-first-fill and recovery in existing-indication volume—while treating the MCT8 revenue ramp as unproven. Falsifier: another guidance cut or continued conversion delays despite added network capacity.
• Over the next 1–3 months, track payer coverage and commercial transitions from EAP, plus net revenue per treated patient; do not extrapolate WAC to sales. Reassess the acquisition case if these data are weak or launch costs push leverage above management’s stated pro forma expectation.
• For a relative-value expression, prefer ANIP over an indiscriminate biotech basket only if Cortrophin conversion improves and the Egetis offer closes on disclosed financing terms; otherwise remain neutral. Key risks are persistent pharmacy bottlenecks, slower-than-expected diagnosis, lower realized pricing, and year-one dilution exceeding the investment case.